secwatch.observer — SEC 8-K summary
======================================

Issuer:     Denali Therapeutics Inc. (DNLI)
CIK:        0001714899
Form:       8-K
Filed at:   2025-01-13T23:59:59+00:00
Accession:  0001714899-25-000054
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Denali tividenofusp alfa gets FDA Breakthrough Therapy; BLA submission in early 2025
--------------------------------------------------------------------------------

- FDA granted Breakthrough Therapy Designation for tividenofusp alfa in Hunter syndrome (MPS II) on Jan 7, 2025.
- Denali expects BLA submission under accelerated approval pathway in early 2025; U.S. launch targeted late 2025/early 2026.
- Seeking FDA alignment on accelerated approval for DNL126 in Sanfilippo syndrome after CSF HS normalization in Phase 1/2.
- Cash, equivalents, and marketable securities ~$1.28B as of Sep 30, 2024; cash runway extended into 2028.
- Plan to advance 1–2 TV-enabled programs into clinic per year over next three years across ETV, OTV, ATV.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1714899/000171489925000054/0001714899-25-000054-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1714899/000171489925000054/dnli-20250113.htm
  HTML page:      https://secwatch.observer/filing/0001714899-25-000054

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer